PIII Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -20.12% compared to P3 Health Partners, Inc.'s net margin of 0.11%. P3 Health Partners, Inc.'s return on equity of -223.63% beat Astrana Health, Inc.'s return on equity of 1.85%.

P3 Health Partners, Inc. has a consensus price target of $10.25, signalling upside risk potential of 303.54%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 35.82%. Given that P3 Health Partners, Inc. has higher upside potential than Astrana Health, Inc., analysts believe P3 Health Partners, Inc. is more attractive than Astrana Health, Inc..

P3 Health Partners, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

P3 Health Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

P3 Health Partners, Inc. quarterly revenues are $345.3M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. P3 Health Partners, Inc.'s net income of -$69.5M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, P3 Health Partners, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 142.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners, Inc. is 0.01x versus 0.46x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

biote Corp. has a net margin of -20.12% compared to P3 Health Partners, Inc.'s net margin of 19.22%. P3 Health Partners, Inc.'s return on equity of -223.63% beat biote Corp.'s return on equity of --.

P3 Health Partners, Inc. has a consensus price target of $10.25, signalling upside risk potential of 303.54%. On the other hand biote Corp. has an analysts' consensus of $4.21 which suggests that it could grow by 90.59%. Given that P3 Health Partners, Inc. has higher upside potential than biote Corp., analysts believe P3 Health Partners, Inc. is more attractive than biote Corp..

P3 Health Partners, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison biote Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

P3 Health Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. biote Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners, Inc. pays -- of its earnings as a dividend. biote Corp. pays out -- of its earnings as a dividend.

P3 Health Partners, Inc. quarterly revenues are $345.3M, which are larger than biote Corp. quarterly revenues of $48M. P3 Health Partners, Inc.'s net income of -$69.5M is lower than biote Corp.'s net income of $9.2M. Notably, P3 Health Partners, Inc.'s price-to-earnings ratio is -- while biote Corp.'s PE ratio is 2.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners, Inc. is 0.01x versus 0.40x for biote Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -20.12% compared to P3 Health Partners, Inc.'s net margin of 9.58%. P3 Health Partners, Inc.'s return on equity of -223.63% beat Cryo-Cell International, Inc.'s return on equity of --.

P3 Health Partners, Inc. has a consensus price target of $10.25, signalling upside risk potential of 303.54%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 149.27%. Given that P3 Health Partners, Inc. has higher upside potential than Cryo-Cell International, Inc., analysts believe P3 Health Partners, Inc. is more attractive than Cryo-Cell International, Inc..

P3 Health Partners, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

P3 Health Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 19.06% to investors and pays a quarterly dividend of $0.15 per share. P3 Health Partners, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

P3 Health Partners, Inc. quarterly revenues are $345.3M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. P3 Health Partners, Inc.'s net income of -$69.5M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, P3 Health Partners, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners, Inc. is 0.01x versus 0.87x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.